Cargando…

Results of a two-phased clinical study evaluating a new multiband mucosectomy device for early Barrett’s neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study

BACKGROUND: Multiband mucosectomy (MBM) is the preferred technique for piecemeal resection of early neoplastic lesions in Barrett’s esophagus (BE). The currently most widely used device for MBM is the Duette device. Recently, the Captivator EMR device has come available which might have practical ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Belghazi, K., Schölvinck, D. W., van Berge Henegouwen, M. I., Gisbertz, S. S., Weusten, B. L., Meijer, S. L., Bergman, J. J., Pouw, R. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684496/
https://www.ncbi.nlm.nih.gov/pubmed/30456511
http://dx.doi.org/10.1007/s00464-018-6582-5
_version_ 1783442253378748416
author Belghazi, K.
Schölvinck, D. W.
van Berge Henegouwen, M. I.
Gisbertz, S. S.
Weusten, B. L.
Meijer, S. L.
Bergman, J. J.
Pouw, R. E.
author_facet Belghazi, K.
Schölvinck, D. W.
van Berge Henegouwen, M. I.
Gisbertz, S. S.
Weusten, B. L.
Meijer, S. L.
Bergman, J. J.
Pouw, R. E.
author_sort Belghazi, K.
collection PubMed
description BACKGROUND: Multiband mucosectomy (MBM) is the preferred technique for piecemeal resection of early neoplastic lesions in Barrett’s esophagus (BE). The currently most widely used device for MBM is the Duette device. Recently, the Captivator EMR device has come available which might have practical advantages over the Duette device. METHODS: Phase I was a randomized pre-esophagectomy trial with a non-inferiority design aiming to compare EMR specimens obtained with the Captivator and the Duette device. Primary outcome: max diameter of the EMR specimens, secondary outcomes: min diameter, max thickness of the EMR specimens and resected submucosal stroma. Phase II were clinical pilot cases aiming to evaluate the feasibility of EMR using the Captivator device. Primary outcome was the successful EMR rate and secondary outcomes included procedure time and adverse events. RESULTS: Phase I: 24 EMR specimens (12 pairs) were obtained from six patients. The median max diameter of EMR specimens obtained with the Captivator device was 16 mm [IQR 12–21] versus 18 mm [IQR 13–23] for the Duette device. Non-inferiority of the max diameter of the Captivator specimens could not be demonstrated (median difference 1 mm, 95% CI − 3.26 to + 5.26). However, when using paired analysis, no significant difference was found (p 0.573). In addition, no statistically significant differences were found in the min diameter, max thickness of EMR specimens, and max thickness of resected submucosal stroma. Phase II: 5 BE patients with early neoplastic lesions were included. Successful EMR was achieved in 100%. Median procedure time was 33 min (IQR 25–39). One patient developed transient dysphagia, without signs of stenosis on endoscopy. CONCLUSIONS: EMR of early Barrett’s neoplasia using the Captivator device is comparable to Duette EMR when looking at size of resected specimens. In the first patients, EMR using the Captivator was feasible, resulting in successful resection without acute adverse events.
format Online
Article
Text
id pubmed-6684496
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-66844962019-08-19 Results of a two-phased clinical study evaluating a new multiband mucosectomy device for early Barrett’s neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study Belghazi, K. Schölvinck, D. W. van Berge Henegouwen, M. I. Gisbertz, S. S. Weusten, B. L. Meijer, S. L. Bergman, J. J. Pouw, R. E. Surg Endosc Article BACKGROUND: Multiband mucosectomy (MBM) is the preferred technique for piecemeal resection of early neoplastic lesions in Barrett’s esophagus (BE). The currently most widely used device for MBM is the Duette device. Recently, the Captivator EMR device has come available which might have practical advantages over the Duette device. METHODS: Phase I was a randomized pre-esophagectomy trial with a non-inferiority design aiming to compare EMR specimens obtained with the Captivator and the Duette device. Primary outcome: max diameter of the EMR specimens, secondary outcomes: min diameter, max thickness of the EMR specimens and resected submucosal stroma. Phase II were clinical pilot cases aiming to evaluate the feasibility of EMR using the Captivator device. Primary outcome was the successful EMR rate and secondary outcomes included procedure time and adverse events. RESULTS: Phase I: 24 EMR specimens (12 pairs) were obtained from six patients. The median max diameter of EMR specimens obtained with the Captivator device was 16 mm [IQR 12–21] versus 18 mm [IQR 13–23] for the Duette device. Non-inferiority of the max diameter of the Captivator specimens could not be demonstrated (median difference 1 mm, 95% CI − 3.26 to + 5.26). However, when using paired analysis, no significant difference was found (p 0.573). In addition, no statistically significant differences were found in the min diameter, max thickness of EMR specimens, and max thickness of resected submucosal stroma. Phase II: 5 BE patients with early neoplastic lesions were included. Successful EMR was achieved in 100%. Median procedure time was 33 min (IQR 25–39). One patient developed transient dysphagia, without signs of stenosis on endoscopy. CONCLUSIONS: EMR of early Barrett’s neoplasia using the Captivator device is comparable to Duette EMR when looking at size of resected specimens. In the first patients, EMR using the Captivator was feasible, resulting in successful resection without acute adverse events. Springer US 2018-11-19 2019 /pmc/articles/PMC6684496/ /pubmed/30456511 http://dx.doi.org/10.1007/s00464-018-6582-5 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Belghazi, K.
Schölvinck, D. W.
van Berge Henegouwen, M. I.
Gisbertz, S. S.
Weusten, B. L.
Meijer, S. L.
Bergman, J. J.
Pouw, R. E.
Results of a two-phased clinical study evaluating a new multiband mucosectomy device for early Barrett’s neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study
title Results of a two-phased clinical study evaluating a new multiband mucosectomy device for early Barrett’s neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study
title_full Results of a two-phased clinical study evaluating a new multiband mucosectomy device for early Barrett’s neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study
title_fullStr Results of a two-phased clinical study evaluating a new multiband mucosectomy device for early Barrett’s neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study
title_full_unstemmed Results of a two-phased clinical study evaluating a new multiband mucosectomy device for early Barrett’s neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study
title_short Results of a two-phased clinical study evaluating a new multiband mucosectomy device for early Barrett’s neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study
title_sort results of a two-phased clinical study evaluating a new multiband mucosectomy device for early barrett’s neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684496/
https://www.ncbi.nlm.nih.gov/pubmed/30456511
http://dx.doi.org/10.1007/s00464-018-6582-5
work_keys_str_mv AT belghazik resultsofatwophasedclinicalstudyevaluatinganewmultibandmucosectomydeviceforearlybarrettsneoplasiaarandomizedpreesophagectomytrialandapilottherapeuticpilotstudy
AT scholvinckdw resultsofatwophasedclinicalstudyevaluatinganewmultibandmucosectomydeviceforearlybarrettsneoplasiaarandomizedpreesophagectomytrialandapilottherapeuticpilotstudy
AT vanbergehenegouwenmi resultsofatwophasedclinicalstudyevaluatinganewmultibandmucosectomydeviceforearlybarrettsneoplasiaarandomizedpreesophagectomytrialandapilottherapeuticpilotstudy
AT gisbertzss resultsofatwophasedclinicalstudyevaluatinganewmultibandmucosectomydeviceforearlybarrettsneoplasiaarandomizedpreesophagectomytrialandapilottherapeuticpilotstudy
AT weustenbl resultsofatwophasedclinicalstudyevaluatinganewmultibandmucosectomydeviceforearlybarrettsneoplasiaarandomizedpreesophagectomytrialandapilottherapeuticpilotstudy
AT meijersl resultsofatwophasedclinicalstudyevaluatinganewmultibandmucosectomydeviceforearlybarrettsneoplasiaarandomizedpreesophagectomytrialandapilottherapeuticpilotstudy
AT bergmanjj resultsofatwophasedclinicalstudyevaluatinganewmultibandmucosectomydeviceforearlybarrettsneoplasiaarandomizedpreesophagectomytrialandapilottherapeuticpilotstudy
AT pouwre resultsofatwophasedclinicalstudyevaluatinganewmultibandmucosectomydeviceforearlybarrettsneoplasiaarandomizedpreesophagectomytrialandapilottherapeuticpilotstudy